Prudentia Sciences Announces Series A Led by McKesson Ventures, Accelerating Due Diligence for Life Sciences Dealmaking

Prudentia Sciences, a pioneer in AI-native due diligence for life sciences dealmaking, today announced that it has secured $20 million in Series A financing. The round was led by McKesson Ventures with participation from SignalFire. Existing investors include Iaso Ventures, Virtue and GV. This brings the company’s total funding to $27 million, following a $7 million seed round in 2024.

Prudentia Sciences provides an AI-native platform that enables pharma companies, biotechs, and financial institutions to evaluate breakthrough medicines with unprecedented speed and rigor. By synthesizing complex clinical signals into actionable insights, Prudentia accelerates deal throughput and provides strategic leverage for acquisition, licensing, or investment decisions made by business development, investment, and diligence teams.

The company’s human-in-the-loop approach orchestrates seamless collaboration between buyers, sellers, and intermediaries. This ensures a secure, compliant infrastructure for the industry’s most critical investment decisions.

“Prudentia is modernizing the way life sciences organizations harness data to evaluate assets and proactively manage risk,” said Dave Schulte, President, McKesson Ventures. “Their AI-native platform accelerates scientific due diligence with real-time insights, seamless integration, and intelligent automation - transforming a traditionally fragmented process into a connected, agile, and future-ready workflow.”

With this new capital, Prudentia Sciences will expand product capabilities, deepen intelligence for both technical and non-technical diligence, and scale commercial operations, including expansion to the Asia-Pacific and Europe.

Prudentia creates a single, continuously updated source of truth for diligence, allowing teams to align faster and make high-stakes investment and partnering decisions with confidence with fully explainable AI.

“Life sciences dealmaking is inherently complex and time-intensive, with substantial capital and scientific innovation at stake,” said Sadiqa Mahmood, Founder and CEO of Prudentia Sciences. “Biotechs struggle to present their assets with clarity and rigor, while pharma teams are forced to balance speed with thorough diligence. Without an intelligent platform to bridge this gap, diligence remains fragmented and high-risk. Prudentia collapses the distance between technical data and strategic conviction, enabling teams to make confident go-or-no-go decisions in a fraction of the time.”

For more information, visit www.prudentiasciences.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260106972777/en/